Cargando…
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been observed, i...
Autores principales: | Wang, Dongxu, Lin, Jianzhen, Yang, Xu, Long, Junyu, Bai, Yi, Yang, Xiaobo, Mao, Yilei, Sang, Xinting, Seery, Samuel, Zhao, Haitao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480748/ https://www.ncbi.nlm.nih.gov/pubmed/31014381 http://dx.doi.org/10.1186/s13045-019-0730-9 |
Ejemplares similares
-
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017) -
Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018) -
Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
por: Wang, Dongxu, et al.
Publicado: (2020) -
Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021) -
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)